Glanzmann Thrombasthenia
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
ITGB3,
ITGA2B,
HPSE,
MTHFR,
EEF1B2P2,
POU2F3,
BHLHE22,
GP1BA,
GP6,
NAAA,
SELP,
TBX1,
THRA,
TLN1,
VTN,
FERMT3,
VWF,
PLA2G6,
TUBB1,
NR1D1,
KCNMB2,
PLA2G1B,
GOLPH3,
HPSE2,
KCNMB3,
PLA2G2A,
ACTB,
NAGLU,
FN1,
CD34
ITGB3,
ITGA2B,
HPSE,
MTHFR,
EEF1B2P2,
POU2F3,
BHLHE22,
GP1BA,
GP6,
NAAA,
SELP,
TBX1,
THRA,
TLN1,
VTN,
FERMT3,
VWF,
PLA2G6,
TUBB1,
NR1D1,
KCNMB2,
PLA2G1B,
GOLPH3,
HPSE2,
KCNMB3,
PLA2G2A,
ACTB,
NAGLU,
FN1,
CD34,
CD40LG,
CD63,
CGA,
DLD,
F5,
F10,
FCGR2A,
GH1,
BRCA1,
HLA-A,
ITGA2,
ITGAV,
ITGB2,
LAD1,
LAMP1,
LGALS1,
LGALS8,
PRB2
Drugs
—
Registered!
Glanzmann thrombasthenia (GT) is a bleeding syndrome characterized by spontaneous mucocutaneous bleeding and an exaggerated response to trauma due to a constitutional thrombocytopenia.